Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Moderna, Inc.
Age limit wasn’t part of advisory committee’s vote on third shot of the COVID vaccine, but aligns with concerns about myocarditis in younger recipients.
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.
Coronavirus Notebook: UK Rolls Out Ronapreve To Hospitalized Patients, Drug Safety Unit Reviews mRNA Vaccine Heart Inflammation Link
Pressure is growing on richer countries to share their excess vaccine doses, and the European Parliament has passed legislation intended to strengthen the EU’s health security framework and make joint vaccine procurement more transparent.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.